Nuvation Bio (NUVB) Cash from Financing Activities (2020 - 2026)
Nuvation Bio (NUVB) posted quarterly Cash from Financing Activities of $44000.0 for Q1 2026, down 91.97% year-over-year from $548000.0 in Q1 2025, and down 99.45% quarter-over-quarter from $8.1 million in Q4 2025.
Powered by 
Analysis
Nuvation Bio (NUVB) Cash from Financing Activities (2020 - 2026) Analysis & Trends
Nuvation Bio (NUVB) has reported Cash from Financing Activities for 7 consecutive years, with $44000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Financing Activities fell 91.97% year-over-year to $44000.0; the TTM figure through Mar 2026 stood at $202.0 million (up 23446.74% YoY), while the FY2025 annual figure was $202.5 million, up 61088.82% from the prior year.
- Cash from Financing Activities slipped to $44000.0 in Q1 2026 per NUVB's latest filing, from $8.1 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $193.4 million in Q2 2025 and bottomed at -$3.6 million in Q2 2022.
- Historically, Cash from Financing Activities has averaged $12.1 million across 5 years, with a median of $258000.0 in 2022.
- Annual changes were most pronounced in 2022 — Cash from Financing Activities sank 6419.3% — and 2025, when it soared 6938.68%.
- Nuvation Bio's Cash from Financing Activities stood at $407000.0 in 2022, then tumbled by 70.52% to $120000.0 in 2023, then plunged by 850.0% to -$900000.0 in 2024, then soared by 995.89% to $8.1 million in 2025, then plunged by 99.45% to $44000.0 in 2026.
- Business Quant data shows NUVB's Cash from Financing Activities at $44000.0 in Q1 2026, $8.1 million in Q4 2025, and $501000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 14.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.42 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -6.05 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 36.24 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -273.15 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Nuvation Bio | 2.38 Bn | 2.38 Bn | 30.78 Mn | 170.53 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 170.53 Mn |
| Mar 31, 2026 | 44,000.00 |
| Dec 31, 2025 | 8.06 Mn |
| Sep 30, 2025 | 501,000.00 |
| Jun 30, 2025 | 193.42 Mn |
| Mar 31, 2025 | 548,000.00 |
| Dec 31, 2024 | -900,000.00 |
| Sep 30, 2024 | -1.54 Mn |
| Jun 30, 2024 | 2.75 Mn |
| Mar 31, 2024 | 21,000.00 |
| Dec 31, 2023 | 120,000.00 |
| Sep 30, 2023 | 77,000.00 |
| Jun 30, 2023 | 133,000.00 |
| Mar 31, 2023 | 298,000.00 |
| Dec 31, 2022 | 407,000.00 |
| Sep 30, 2022 | 258,000.00 |
| Jun 30, 2022 | -3.60 Mn |
| Mar 31, 2022 | 4.26 Mn |
| Dec 31, 2021 | 538,000.00 |
| Sep 30, 2021 | -32,000.00 |